trientine dihydrochloride

DRUG3 trials

Sponsors

Univar BV, National Cheng-Kung University Hospital

Conditions

Fallopian Tube CancerOvarian Neoplasms Malignant (Excl Germ Cell)Peritoneal CarcinomaWilson DiseaseWilson's Disease

Phase 1

A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients

CompletedNCT01874028

Univar BVWilson's Disease

Start: 2013-05-31End: 2014-03-31Updated: 2014-09-19

Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer

CompletedNCT03480750

National Cheng-Kung University HospitalFallopian Tube Cancer, Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma

Start: 2012-09-30End: 2019-12-31Updated: 2020-11-10

Phase 4

Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine

Univar BVWilson Disease

Start: 2016-01-31End: 2018-07-31Target: 90Updated: 2017-08-23

Related Papers

Prospective Study to Assess Long‐Term Outcomes of Chelator‐Based Treatment With Trientine Dihydrochloride in Patients With Wilson Disease

JGH Open2025-03-01

Multicentre, retrospective study to assess long-term outcomes of chelator based treatment with trientine in Wilson disease patients withdrawn from therapy with d -penicillamine.

PubMed2022-09-016 citations

A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy

Frontiers in Oncology2019-05-2434 citations